Wiborg ApS and Avance GmbH enter agreement on state-of-art valuation software

Wiborg ApS and Avance GmbH enter agreement on state-of-art valuation software

Wiborg ApS and Avance GmbH enter agreement on state-of-art valuation software Basel, Switzerland and Copenhagen, Denmark, (July 1, 2008). Avance GmbH and Wiborg ApS have entered into a collaboration agreement under which Wiborg ApS has been appointed the exclusive distributor for the ri:val® system in the Nordic and Baltic countries. Ri:val® is an advanced software tool that is rapidly becoming the standard for valuation of technology, products and companies in the life sciences industry.

Biotech and pharmaceutical companies routinely apply valuation as part of their licensing and partnering programs. In addition, project valuations are an integral part of portfolio management and financial reporting. However, most companies have so far mainly applied in-house developed ad hoc spreadsheets that do not always meet the rising demands for accuracy and reproducibility in the industry. The ri:val® software is a robust solution that addresses these needs in an integrated manner.

In addition to the distribution of ri:val® in the Nordic and Baltic region, Avance and Wiborg will collaborate on providing expert consultancy on valuation and licensing to companies and investors in the life science area.

–        “We are extremely pleased to have entered into this collaboration”, says Ralph Villiger, Partner in Avance GmbH, and continues: “With their knowledge and experience of the pharmaceutical and biotech industry, together with their network in Scandinavia, Wiborg is a perfect match for us. We look forward to a long-standing partnership.”
–  “We have been very impressed with the ri:val®  software which we think is the best ready-to-use solution to valuation assessment of drug development and life science projects”, says Ole Wiborg, Managing Partner in Wiborg ApS. “Adding this software and the access to the valuation competencies in Avance is completely in line with our strategy to strengthen our position as an expert consultancy house to the Nordic biotech and pharma community”.

is the leading valuation solution for business developers, investors, CFOs and CEOs in pharma and biotech. ri:val® generates valuation results far beyond any error-prone spreadsheet calculation and allows to quickly explore multiple scenarios. In addition, the software provides access to up-to-date industry data on drug development.

Avance GmbH
Avance GmbH is a service and solution provider located in Basel and San Francisco. The company serves a wide range of clients around the globe including biotechs, big pharma, hedge funds, venture capitalists, banks, and technology transfer offices.
The company works in close collaboration with external advisors in the field of market forecasting, clinical trials, and regulatory affairs.

Wiborg ApS
Wiborg ApS is a consulting firm that assists academic groups, tech transfer units and biotech/pharma companies in licensing, market analysis, business development and technology/company valuation. The company operates globally with its customers mainly located in Scandinavia.

For more information contact
Ralph Villiger, Partner

tel: +41 76 321 90 86

Ole Wiborg, Managing Partner

tel: +45 4587 1910

ScanBalt members: